• Crizotinib hydrochloride: Reliable ALK Kinase Inhibition in

  2026-08-03

  This article presents evidence-backed strategies for integrating Crizotinib hydrochloride (SKU B3608) into advanced cancer biology workflows. Through real laboratory scenarios, it demonstrates how this ATP-competitive ALK kinase inhibitor offers reproducible inhibition of oncogenic signaling, supports robust data interpretation, and enhances compatibility with assembloid models. Benchmarking against common alternatives, the article positions SKU B3608 as a dependable choice for researchers demanding high purity and consistent results.

• Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP): Mechanisms & Be

  2026-08-03

  Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) enables robust, low-immunogenicity bioluminescent reporting for gene expression and cell viability assays. Incorporating ARCA capping and nucleotide modifications, this reagent delivers enhanced stability and translation efficiency. Benchmark data confirm its reliability as a gold-standard reporter in high-sensitivity workflows.

• Lipo3K Transfection Reagent: High-Efficiency Gene Modulation

  2026-08-02

  Lipo3K Transfection Reagent delivers superior nucleic acid transfection, even in challenging cell lines, enabling robust gene expression and RNA interference studies. Its unique formulation with Lipo3K-A enhancer boosts nuclear DNA delivery while minimizing cytotoxicity, setting a new standard for DNA and siRNA co-transfection workflows.

• BHPF as a GPER Inhibitor: Mechanisms in Neuroblastoma Apopto

  2026-08-01

  This study reveals that fluorene-9-bisphenol (BHPF), a BPA substitute, acts as a direct inhibitor of the G protein-coupled estrogen receptor 1 (GPER) in human neuroblastoma cells. Using molecular dynamics and functional assays, the research elucidates the binding mechanism, functional inhibition profile, and distinguishes BHPF from established antagonists, informing both risk assessment and experimental workflows in estrogen signaling research.

• miR-18a/ALOXE3 Axis Drives Ferroptosis Resistance in Gliobla

  2026-07-31

  This study uncovers how miR-18a promotes glioblastoma progression by downregulating ALOXE3, reducing ferroptosis and enhancing tumor cell migration via altered lipid metabolism and Gs-protein-coupled signaling. The findings offer mechanistic clarity on miRNA-driven ferroptosis resistance, highlighting new molecular targets for GBM research.

• Reserpine (N1867): Technical Guidance for Lab Research Workf

  2026-07-31

  Reserpine (SKU N1867) is a high-purity, research-only standard essential for controlled neurotransmitter depletion, antihypertensive mechanism studies, and neuropharmacology research. It is not suitable for diagnostic, clinical, or veterinary applications, and requires rigorous handling and storage protocols for reproducible results.

• Foretinib (GSK1363089): Dissecting Multikinase Inhibition Dy

  2026-07-30

  Explore how Foretinib (GSK1363089) uniquely modulates cancer cell proliferation and metastasis via nuanced kinase inhibition. This article provides a deep-dive into assay design, mechanistic insights, and the evolving understanding of drug response metrics in oncology research.

• Cabozantinib (XL184) in RCC: Protocols, Adaptation & Trouble

  2026-07-30

  Cabozantinib (XL184) empowers RCC researchers to dissect timescale-dependent kinase signaling and antiangiogenic adaptation with precision. This article translates recent phosphoproteomic breakthroughs into actionable protocols, troubleshooting strategies, and advanced applications for robust and reproducible cancer research.

• Microglial Activation and Hippocampal Dysregulation in Alcoh

  2026-07-29

  This study uncovers how acute alcohol exposure increases seizure susceptibility by activating microglia in the hippocampus, which disrupts the balance of GABAergic and glutamatergic synaptic formation. The findings advance our understanding of neuroimmune mechanisms in alcohol-related seizure risk and offer a foundation for targeted translational research.

• Lipo3K Transfection Reagent: High-Efficiency for Tough Cell

  2026-07-29

  Lipo3K Transfection Reagent redefines nucleic acid delivery for challenging cell types by combining robust efficiency with minimized cytotoxicity. Its dual-component system and protocol flexibility empower advanced gene expression and RNA interference research, including difficult co-transfection scenarios.

• Pexidartinib (PLX3397) in Tumor Microenvironment Modulation

  2026-07-28

  Pexidartinib (PLX3397) enables highly selective CSF1R inhibition, empowering researchers to dissect macrophage roles in cancer progression and therapy resistance. This article guides experimental design, troubleshooting, and novel applications—anchored by recent breakthroughs in TAM-targeted modulation.

• Novobiocin: Unlocking Translational Value Beyond Antibacteri

  2026-07-28

  This article explores Novobiocin's mechanistic versatility, spanning DNA gyrase inhibition and Hsp90 targeting, and provides actionable insights for translational researchers. Drawing from recent synthetic and biological advances, it contextualizes Novobiocin’s multidomain potential, protocol optimization, and strategic considerations for resistance and antiparasitic research, while highlighting opportunities for innovation beyond traditional antibacterial workflows.

• Hydroxytyrosol: Advancing Antioxidant Workflows in Disease M

  2026-07-27

  Hydroxytyrosol, a phenolic antioxidant from APExBIO, empowers researchers to dissect oxidative stress and inflammation mechanisms with exceptional reproducibility. High purity, versatile solubility, and robust literature support make it ideal for cardiovascular, renal, and inflammation studies where data quality and workflow reliability are paramount.

• Phytochemical-Induced GSTM2 Activation Suppresses Bladder Ca

  2026-07-27

  The referenced study demonstrates that berberrubine, a natural isoquinoline alkaloid, potently upregulates glutathione S-transferase Mu 2 (GSTM2) in human bladder cancer cells through SP1 activation and DNA demethylation. This mechanism inhibits cancer cell proliferation, migration, and invasion, providing novel insight into GSTM2 as both a tumor suppressor and a therapeutic target.

• BMS-777607: Selective c-Met Inhibitor for Cancer and Platele

  2026-07-26

  BMS-777607 is a potent, selective c-Met inhibitor that demonstrates high specificity for MET kinase family members and is validated in cancer metastasis and stem cell-derived platelet protocols. The compound exhibits nanomolar IC50 values and robust in vivo efficacy, with notable selectivity and minimal toxicity. These properties make it a valuable tool in MET signaling pathway inhibition for research.

15460 records 1/1031 page Next 12345 下5页 Last page